Vectura Group PLC Company Profile (LON:VEC)

Analyst Ratings

Consensus Ratings for Vectura Group PLC (LON:VEC) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 226.14

Analysts' Ratings History for Vectura Group PLC (LON:VEC)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016Peel HuntReiterated RatingBuyGBX 200View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 230View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Numis Securities LtdReiterated RatingBuyGBX 264View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Stifel NicolausReiterated RatingBuyGBX 250View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Royal Bank Of CanadaLower Price TargetOutperformGBX 210 -> GBX 205View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016N+1 SingerReiterated RatingBuyGBX 209View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016FinnCapReiterated RatingBuyGBX 225View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2015Canaccord GenuityReiterated RatingBuyGBX 222View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2015Barclays PLCReiterated RatingOverweightGBX 180 -> GBX 180View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015InvestecReiterated RatingHoldGBX 160 -> GBX 192View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015CRT CapitalDowngradeBuy -> Fair ValueGBX 32 -> GBX 30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Oriel Securities LtdReiterated RatingBuyGBX 207View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014Shore CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Vectura Group PLC (LON:VEC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Vectura Group PLC (LON:VEC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vectura Group PLC (LON:VEC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vectura Group PLC (LON:VEC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/7/2016Derodra,AndrewInsiderSell263,364GBX 152£400,313.28Tweet This Trade  Share This Trade on StockTwits
6/17/2016Derodra,AndrewInsiderSell419,661GBX 154£646,277.94Tweet This Trade  Share This Trade on StockTwits
6/13/2016Derodra,AndrewInsiderSell279,774GBX 157£439,245.18Tweet This Trade  Share This Trade on StockTwits
7/7/2015Oakley,Andrew J.InsiderBuy1,000GBX 180£1,800Tweet This Trade  Share This Trade on StockTwits
1/15/2015Trevor PhillipsInsiderSell171,777GBX 144.50£248,217.77Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vectura Group PLC (LON:VEC)
DateHeadline
07/20/16 09:58 AMPeel Hunt reiterated Vectura Group PLC (LON:VEC) as 'Buy' With 200 PT - FTSE News
07/19/16 07:16 PMVectura Group PLC (LON:VEC) target price held steady at 200GBX as announced today by Peel Hunt
07/19/16 08:01 AMVectura Group PLC (LON:VEC) Receives Buy Rating From Peel Hunt Analysts - Fiscal Standard
07/18/16 06:43 AMHow Many Vectura Group PLC (LON:VEC)'s Analysts Are Bearish? - Consumer Eagle
07/15/16 12:24 PMVectura Group (LON:VEC) Broker Price Targets - Fiscal Standard
07/10/16 06:40 AMHow Many Vectura Group PLC (LON:VEC)'s Analysts Are Bearish? - Press Telegraph
07/07/16 07:10 PMJP Morgan Gives Vectura Group PLC Price Target With Potential 47.44% Upside - FTSE News
07/07/16 09:48 AMVectura : Board Committee changes post completion of merger with Skyepharma
07/06/16 07:35 PMJP Morgan Indicates Potential 46.5% Increase In Shares Of Vectura Group PLC - Fiscal Standard
07/06/16 07:35 PMVectura Group PLC 45.6% Potential Upside Indicated by JP Morgan Cazenove - DirectorsTalk Interviews
07/02/16 06:33 PMPeel Hunt disclosed (LON:VEC) Vectura Group PLC, boosting its stock price target to GBX200 earlier today - Breaking Finance News
07/01/16 07:05 PMGroup’s full-year sales and earnings dip in year to March amid currency weakness
07/01/16 09:45 AMInvestec’s latest survey did not capture aftermath of UK’s shock referendum result
07/01/16 09:45 AMVectura Group Says Lyon Manufacturing Facility Lease Returned
07/01/16 09:45 AMLyon manufacturing facility returns to the Vectura Group
07/01/16 09:45 AMVectura Group PLC (LON:VEC) price target maintained to GBX200 as reported today by Peel Hunt
06/30/16 07:17 PMVectura : Licence Option Exercised
06/30/16 09:48 AMVectura Group PLC 23.6% Potential Upside Indicated by Peel Hunt - DirectorsTalk Interviews
06/29/16 06:59 PMVectura : Says Partner Ablynx Exercises Commercial Licence Option
06/28/16 07:00 PMVectura Says Partner Ablynx Exercises Commercial Licence Option
06/28/16 06:32 AMVectura Group (LON:VEC) Analyst Target Prices - FTSE News
06/28/16 04:11 AMLicence Option Exercised - [at noodls] - Vectura Group plc Ablynx to exercise option to license Vectura's FOX device for use in its forthcoming Phase IIb efficacy study of its inhaled anti-RSV Nanobody (ALX-0171) Chippenham, UK - 28 June 2016: ...
06/26/16 05:58 PMVectura Group PLC (VEC) Given Buy Rating at Numis Securities Ltd
06/25/16 06:21 PMVectura Group PLC (LON:VEC) Receives 'Buy' Rating From Brokers At Numis - FTSE News
06/17/16 09:46 AMVectura : Notification of Major Interest In Shares
06/14/16 06:42 PMManikay Partners, LLC UK Regulatory Announcement: Form 8.3 - Vectura Group Plc - Business Wire (press release)
06/12/16 07:10 PMVectura : Company Act 2006 S430 (2B) Disclosure
06/08/16 07:42 PMDimensional Fund Adv UK Regulatory Announcement: Form 8.3 - Vectura Group Plc - Ordinary shares - Business Wire (press release)
06/08/16 10:18 AMForm 8.3 - Vectura Group Plc - Amendment - [at noodls] - LONDON--(BUSINESS WIRE)-- AMENDMENT TO SECTION 2(a) FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of ...
06/08/16 10:15 AMForm 8.3 - Vectura Group Plc - Amendment - Business Wire (press release)
06/03/16 10:10 AMVectura completes safety tests on asthma drug - Proactive Investors UK
06/01/16 10:07 AMVectura Group (LON:VEC) Analyst Target Changes - Share Trading News - Vectura Group (LON:VEC) Analyst Target ChangesShare Trading NewsVectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a ...and more »
06/01/16 10:07 AMINVESCO Limited UK Regulatory Announcement: Form 8.3 - Vectura Group Plc - Business Wire (press release) - INVESCO Limited UK Regulatory Announcement: Form 8.3 - Vectura Group PlcBusiness Wire (press release)Form 8.3 - Vectura Group Plc. June 01, 2016 07:36 AM Eastern Daylight Time. LONDON--(BUSINESS WIRE)--. FORM 8.3. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY. A PERSON WITH INTERESTS IN RELEVANT SECURITIES ...and more »
05/31/16 07:10 AMPipeline of Asthma Market Covering 129 Companies Reviewed for H1 2016 in New Research Report - Inc., Vectura Group Plc, Verona Pharma Plc, WhanIn Pharmaceutical Co., Ltd., Xencor, Inc., Yungjin Pharm. Co., Ltd., Zambon Company S.p.A. and Ziarco Pharma Ltd. Order a copy of Asthma - Pipeline Review, H1 2016 market research report @ http ...
05/31/16 07:10 AMVectura : Form 8.3 - Vectura Group PLC - All interests and all short positions should be disclosed. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). If there are positions or ...
05/25/16 03:51 AMVectura Group Plc breached its 50 day moving average in a Bullish Manner : VEC-GB : May 25, 2016 -
05/24/16 12:34 PMVectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic ... - PR Newswire (press release) - DIGITALLOOKVectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic ...PR Newswire (press release)CHIPPENHAM, United Kingdom and MADISON, Wis., May 24, 2016 /PRNewswire/ -- Vectura Group plc (LSE: VEC) and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that ...Vectura Teams Up With Propeller Health To Combine TechnologyLondon South East (registration) (blog)all 6 news articles »
05/24/16 12:34 PMHargreave Hale Limited UK Regulatory Announcement: Form 8.3 - Vectura Group Plc - Business Wire (press release) - Hargreave Hale Limited UK Regulatory Announcement: Form 8.3 - Vectura Group PlcBusiness Wire (press release)Form 8.3 - Vectura Group Plc. May 24, 2016 06:13 AM Eastern Daylight Time. LONDON--(BUSINESS WIRE)--. FORM 8.3. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY. A PERSON WITH INTERESTS IN RELEVANT SECURITIES ...and more »
05/24/16 05:16 AMMajedie Asset Management Ltd : Form 8.3 - VECTURA GROUP PLC - [at noodls] - FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) ...
05/24/16 05:00 AMVectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases - [PR Newswire] - CHIPPENHAM, United Kingdom and MADISON, Wis., May 24, 2016 /PRNewswire/ -- Vectura Group plc (VEC.L) and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that combine Vectura's proven dry powder inhaler ("DPI") technology with Propeller's FDA-cleared digital health platform. Vectura is a leading respiratory pharmaceutical company providing a range of pre-metered foil blister-based dry powder inhalers developed to meet patients' needs in inhalation therapy.
05/24/16 04:32 AMVectura teams up with Propeller on inhaler plan -
05/24/16 01:06 AMVectura & Propeller Health announce collaboration - [at noodls] - Vectura Group plc Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases Chippenham, UK and Madison, Wisconsin, USA - 24 May ...
05/22/16 01:26 PMAlliance Trust PLC : Form 8.3 - Vectura Group PLC - If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short ...
05/20/16 12:19 PMForm 8.5 (EPT/RI) - Vectura Group Plc - Stockhouse - Form 8.5 (EPT/RI) - Vectura Group PlcStockhouseVectura Group Plc. (c) Name of the party to the offer with which exempt principal trader is connected: Skyepharma Plc. (d) Date dealing undertaken: 18 May 2016. (e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect ...and more »
05/20/16 02:33 AMRecommended all share merger - [at noodls] - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE ...
05/19/16 11:56 AMSkyepharma Continues To Expect Strong Growth In Revenues For 2016 - Quick Facts - The company said it looks forward to the future with confidence, following the overwhelming shareholder vote earlier this month in support of the board's recommended all-share merger with Vectura Group plc.
05/19/16 11:56 AMABERFORTH PARTNERS LLP - Form 8.3 - Vectura Group plc - PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror ...
05/17/16 12:55 PMBRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma deal - Reuters - BRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma dealReutersBRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma deal. May 16 Competitions and Markets Authority. * UK's CMA says decided that a relevant merger situation has not been created in anticipated acquisition by Vectura Group Plc of ...
05/17/16 12:55 PMBRIEF-Vectura Group says CMA not to investigate Vectura-Skyepharma merger - Reuters - BRIEF-Vectura Group says CMA not to investigate Vectura-Skyepharma mergerReutersMay 16 Vectura Group Plc : * CMA has confirmed that proposed recommended all share merger of Vectura and Skyepharma does not qualify for investigation. * Confirmation satisfies CMA clearance condition to implementation of proposed merger Source text ...
05/17/16 12:55 PMVectura Group PLC (LON:VEC) Receives 'Buy' Rating From Numis Securities - Share Trading News - Share Trading NewsVectura Group PLC (LON:VEC) Receives 'Buy' Rating From Numis SecuritiesShare Trading NewsOn Monday Numis Securities reiterated its rating on shares of Vectura Group PLC as 'Buy' issuing a recommended target price of 264 potentially meaning there is an increase of 55.57% from Vectura Group PLC's share price of 169.7. Vectura Group PLC has ...Vectura Group PLC (LON:VEC) Stock Rating Reconfirmed by Analysts at Stifel; The GBX 250.00 Target Indicates 47.32 ...Wall Street Hints and Newsall 378 news articles »

Social

About Vectura Group PLC

Vectura Group PLC logoVectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies. Its portfolio comprises partnered and licensed marketed products, as well as branded and generic investigational drugs. It has various products in the pipeline, which include VR588, VR942, VR475, VR465, VR096, VR647, VR179, VR736, VR876, NVA237, QVA149, VR315, VR506 and VR632. Its marketed products include Ultibro Breezhaler, Seebri Breezhaler, AirFluSal Forspiro, ADVATE and Adept. Its licensed products include Anoro Ellipta, Relvar Ellipta/Breo Ellipta and Incruse Ellipta. It also has a range of technology platforms, which include formulation technologies, such as PowderHale and ParticleMAX, and device technology, such as GyroHaler.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: VEC
  • CUSIP:
Key Metrics:
  • Previous Close: $2.09
  • 50 Day Moving Average: $156.49
  • 200 Day Moving Average: $164.74
  • P/E Ratio: 129.50
  • P/E Growth: 0.00
  • Market Cap: $638.10M
  • Current Year EPS Consensus Estimate: $3.20 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: